Testosterone, most of which is produced in men’s testes or replicated chemically by companies including Bayer AG, Eli Lilly & Co. (LLY) and AbbVie Inc. (ABBV), is already in demand.
Revenue from prescription sales in the U.S. grew tenfold to $2.2 billion since 2001. Newer topical gel formulations are spurring 20 percent-a-year growth in the market, which will reach $5 billion by 2017, Global Industry Analyst Inc., a San Jose, California-based research firm, said last April.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.